Redefining Treatment Approaches in Advanced Triple-Negative Breast Cancer

Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer

Panelists break down data from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer.

Panelists highlight findings from the ASCENT-03 trial evaluating sacituzumab govitecan in triple-negative breast cancer ineligible for immunotherapy.

Panelists discuss safety considerations for sacituzumab govitecan–based therapy in frontline triple-negative breast cancer.

Panelists discuss sequencing considerations as more TROP-2–directed antibody-drug conjugates are evaluated in triple-negative breast cancer.

Panelists discuss findings from the TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan in immunotherapy-ineligible triple-negative breast cancer.

Panelists break down other key triple-negative breast cancer data presented at the 2025 ESMO Congress.

Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.